Healthcare provider profile · identity verified

Reneeta Basu, D.O.

Family Practice · LILBURN, GA · NPI 1003235417

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	357	109
Amlodipine Besylate	Amlodipine Besylate	282	90
Metformin Hcl	Metformin Hcl	162	52
Rosuvastatin Calcium	Rosuvastatin Calcium	148	60
Lisinopril	Lisinopril	142	45
Hydrochlorothiazide	Hydrochlorothiazide	136	51
Losartan Potassium	Losartan Potassium	126	39
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	109	37
Levothyroxine Sodium	Levothyroxine Sodium	107	35
Albuterol Sulfate Hfa	Albuterol Sulfate	89	43
Metoprolol Tartrate	Metoprolol Tartrate	74	21
Omeprazole	Omeprazole	69	22
Ozempic	Semaglutide	62	17
Alendronate Sodium	Alendronate Sodium	61	22
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	61	18
Glipizide	Glipizide	58	15
Pantoprazole Sodium	Pantoprazole Sodium	56	24
Carvedilol	Carvedilol	51	20
Tamsulosin Hcl	Tamsulosin Hcl	47	18
Gabapentin	Gabapentin	46	22
Metoprolol Succinate	Metoprolol Succinate	45	17
Fluticasone Propionate	Fluticasone Propionate	38	20
Sertraline Hcl	Sertraline Hcl	38	12
Simvastatin	Simvastatin	37	14
Potassium Chloride	Potassium Chloride	35	16
Escitalopram Oxalate	Escitalopram Oxalate	33	12
Allopurinol	Allopurinol	32	13
Jardiance	Empagliflozin	30	13
Valsartan	Valsartan	29	12
Furosemide	Furosemide	28	11
Trazodone Hcl	Trazodone Hcl	28	suppressed
Ezetimibe	Ezetimibe	27	suppressed
Lovastatin	Lovastatin	27	suppressed
Donepezil Hcl	Donepezil Hcl	26	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	26	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	26	suppressed
Pravastatin Sodium	Pravastatin Sodium	26	suppressed
Duloxetine Hcl	Duloxetine Hcl	24	suppressed
Fenofibrate	Fenofibrate	24	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	24	20
Wixela Inhub	Fluticasone Propion/Salmeterol	24	suppressed
Famotidine	Famotidine	23	11
Glipizide Er	Glipizide	23	12
Januvia	Sitagliptin Phosphate	22	suppressed
Montelukast Sodium	Montelukast Sodium	22	11
Triamcinolone Acetonide	Triamcinolone Acetonide	22	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	21	14
Hydralazine Hcl	Hydralazine Hcl	21	suppressed
Methylprednisolone	Methylprednisolone	21	20
Glimepiride	Glimepiride	20	suppressed
Klor-Con M20	Potassium Chloride	20	suppressed
Valacyclovir	Valacyclovir Hcl	20	13
Ondansetron Hcl	Ondansetron Hcl	19	suppressed
Chlorthalidone	Chlorthalidone	18	suppressed
Citalopram Hbr	Citalopram Hydrobromide	18	suppressed
Clonidine Hcl	Clonidine Hcl	18	suppressed
Clopidogrel	Clopidogrel Bisulfate	18	suppressed
Metformin Hcl Er	Metformin Hcl	18	suppressed
Memantine Hcl	Memantine Hcl	17	suppressed
Novolog Flexpen	Insulin Aspart	16	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	15	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	15	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	15	suppressed
Prednisone	Prednisone	15	14
Atenolol	Atenolol	14	suppressed
Nifedipine Er	Nifedipine	14	suppressed
Spironolactone	Spironolactone	14	suppressed
Diclofenac Sodium	Diclofenac Sodium	13	suppressed
Levetiracetam	Levetiracetam	13	suppressed
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	13	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	13	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	13	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	12	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	12	suppressed
Xarelto	Rivaroxaban	12	suppressed
Clonazepam	Clonazepam	11	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	11	suppressed
Synthroid	Levothyroxine Sodium	11	suppressed
Ventolin Hfa	Albuterol Sulfate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error